Gapping up
In reaction to earnings/guidance/SSS: OOMA +10.5%, MEI +6.2%, SEAC +4.5%, PLNT +1.4%, OXM +0.5%, CPB +0.5%, COST +0.4%
M&A news: LCI MM +29.1% (to be acquired by Verizon's (VZ) AOL for $1.75/share), +15.4% (to acquire Kremers Urban Pharmaceuticals for $1.23 bln; expects the deal to be accretive to adjusted EPS in FY16 in the mid-high single digits and 20-25% in FY17)
Select EU related names showing strength: ASML +3.1%, ERIC +1.9%, AZN +1.8%, SNY +1.6%, MU +1%, NVO +0.9%
Other news: GERN +19.3% (announces publication of two papers in The New England Journal of Medicine that highlight the potential of imetelstat in hematologic malignancies ), ISR +9% (extended its international distribution agreement with Karlheinz Goehl-Medizintechnik Goehl), ACAD +9% (submits a New Drug Application to the FDA seeking approval for NUPLAZID for the treatment of psychosis associated with Parkinson's disease), CYTX +7.6% (announced that the first patient has been enrolled and treated in the ADRESU trial), SUNE +3.8% (Bloomberg profiles interview CEO who indicated cash flows might be coming in 2016), TTPH +3.2% (announces that the FDA has granted Qualified Infectious Disease Product and Fast Track designations for IV TP-271), SYT +2.8% (authorizes $2 bln share repurchase program; divests seed business; reiterates the full year guidance), MNOV +2.5% (reports the first advanced ALS patient enrolled in Phase 2 clinical trial of MN-166), ARMH +2.3% (IBM (IBM) announced an expansion of its Internet of Things platform -- called IBM IoT Foundation - through an integration with ARM (ARMH)),DOW +2% (commences its exchange offer for the split-off of a significant portion of its chlorine value chain ), NAVB +2% (awarded a $1.8M fast track NIH SBIR grant for the evaluation of Tc99m tilmanocept), TSLA +1.9% (Musk tweets "Model 3, our smaller and lower cost sedan will start production in about 2 years. Fully operational Gigafactory needed."), ATRO +0.9% (selected to supply the Passenger Service Units, on a new family of long-range Boeing (BA) 777X aircraft), NUE +0.8% (announced $900 mln share repurchase program)
Analyst comments: FMS +3.4% (upgraded to Buy at Goldman), FRAN +2.5% (upgraded to Outperform at Wedbush), SFUN +2% (upgraded to Buy at Credit Agricole), HAL +1.6% (upgraded to Buy at HSBC), SLB +1.2% (upgraded to Buy at Citigroup), FR +1.1% (upgraded to Outperform at Raymond James), EBAY +1% (upgraded to Neutral at Piper Jaffray
)
In reaction to earnings/guidance/SSS: OOMA +10.5%, MEI +6.2%, SEAC +4.5%, PLNT +1.4%, OXM +0.5%, CPB +0.5%, COST +0.4%
M&A news: LCI MM +29.1% (to be acquired by Verizon's (VZ) AOL for $1.75/share), +15.4% (to acquire Kremers Urban Pharmaceuticals for $1.23 bln; expects the deal to be accretive to adjusted EPS in FY16 in the mid-high single digits and 20-25% in FY17)
Select EU related names showing strength: ASML +3.1%, ERIC +1.9%, AZN +1.8%, SNY +1.6%, MU +1%, NVO +0.9%
Other news: GERN +19.3% (announces publication of two papers in The New England Journal of Medicine that highlight the potential of imetelstat in hematologic malignancies ), ISR +9% (extended its international distribution agreement with Karlheinz Goehl-Medizintechnik Goehl), ACAD +9% (submits a New Drug Application to the FDA seeking approval for NUPLAZID for the treatment of psychosis associated with Parkinson's disease), CYTX +7.6% (announced that the first patient has been enrolled and treated in the ADRESU trial), SUNE +3.8% (Bloomberg profiles interview CEO who indicated cash flows might be coming in 2016), TTPH +3.2% (announces that the FDA has granted Qualified Infectious Disease Product and Fast Track designations for IV TP-271), SYT +2.8% (authorizes $2 bln share repurchase program; divests seed business; reiterates the full year guidance), MNOV +2.5% (reports the first advanced ALS patient enrolled in Phase 2 clinical trial of MN-166), ARMH +2.3% (IBM (IBM) announced an expansion of its Internet of Things platform -- called IBM IoT Foundation - through an integration with ARM (ARMH)),DOW +2% (commences its exchange offer for the split-off of a significant portion of its chlorine value chain ), NAVB +2% (awarded a $1.8M fast track NIH SBIR grant for the evaluation of Tc99m tilmanocept), TSLA +1.9% (Musk tweets "Model 3, our smaller and lower cost sedan will start production in about 2 years. Fully operational Gigafactory needed."), ATRO +0.9% (selected to supply the Passenger Service Units, on a new family of long-range Boeing (BA) 777X aircraft), NUE +0.8% (announced $900 mln share repurchase program)
Analyst comments: FMS +3.4% (upgraded to Buy at Goldman), FRAN +2.5% (upgraded to Outperform at Wedbush), SFUN +2% (upgraded to Buy at Credit Agricole), HAL +1.6% (upgraded to Buy at HSBC), SLB +1.2% (upgraded to Buy at Citigroup), FR +1.1% (upgraded to Outperform at Raymond James), EBAY +1% (upgraded to Neutral at Piper Jaffray
)